Investors Buy Large Volume of NewLink Genetics Call Options (NLNK)
NewLink Genetics Corp (NASDAQ:NLNK) saw some unusual options trading on Friday. Traders purchased 7,130 call options on the stock. This represents an increase of approximately 1,864% compared to the typical daily volume of 363 call options.
NLNK has been the topic of several analyst reports. Zacks Investment Research upgraded NewLink Genetics from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Tuesday, November 7th. Jefferies Group cut their target price on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Stifel Nicolaus lifted their target price on NewLink Genetics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics in a research note on Thursday, November 2nd. Finally, Bank of America initiated coverage on NewLink Genetics in a research note on Friday, October 13th. They issued a “buy” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $23.29.
Several hedge funds have recently modified their holdings of NLNK. Perceptive Advisors LLC purchased a new stake in shares of NewLink Genetics during the third quarter worth about $4,581,000. Candriam Luxembourg S.C.A. grew its stake in shares of NewLink Genetics by 337.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock worth $3,339,000 after acquiring an additional 253,000 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of NewLink Genetics by 207.1% during the third quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock worth $3,176,000 after acquiring an additional 210,360 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of NewLink Genetics during the third quarter worth about $1,819,000. Finally, GSA Capital Partners LLP grew its stake in shares of NewLink Genetics by 653.7% during the third quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock worth $1,345,000 after acquiring an additional 114,620 shares during the last quarter. Institutional investors and hedge funds own 52.63% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/investors-buy-large-volume-of-newlink-genetics-call-options-nlnk/1798245.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.